$0.69
-0.01(-0.73%)
Mkt Cap $13M
$0.63
$6.20
52-Week Range
At a Glance
AI-generatedFY2025 delivered material loss reductions for Genenta Science, driven by targeted cost optimization across R&D and administrative operations.
6-K
Genenta Science S.p.A. (evolving into Saentra Forge) has entered into a binding offer to acquire up to a 51% controlling stake in Sòphia High Tech S.r.l., an Italian aerospace and defense engineering and manufacturing company, through a two-phase transaction involving capital increases and share purchases, subject to due diligence and approvals.$13M
Market Cap
—
Revenue
-$8M
Net Income
Employees13
Fundamentals
How The Business Makes Money
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Industry Biotechnology
Activity
Company Profile
CIK0001838716
ISINUS36870W1009
CUSIP36870W100
Phone39 02 26 43 46 81
AddressVia Olgettina No. 58, Milan, MI, 20132, IT
SEC EDGAR